Michael S. Gilmore (USA)
Sir William Osler Professor and Director
Department of Ophthalmology (Microbiology and Immunobiology)
Infectious Disease Institute
Michael S. Gilmore is the founder and Principal Investigator of the Harvard-wide Program on Antibiotic Resistance, and of the academic/industry consortium Boston-Area Antibiotic Resistance Network (BAARN, www.abresistance.net). His research focuses on the evolution and development of multidrug resistant strains of enterococci, streptococci and staphylococci, and the development of new therapeutic approaches. Currently, he is developing new ways to prevent and treat the most problematic multidrug resistant infections. He serves on numerous advisory boards and committees for public (NIH, FDA, VA, NSF, EU) and private organizations, mainly focused on drug discovery, antibiotic resistance, and bacterial pathogenesis. Dr. Gilmore's laboratory focuses on developing new ways to treat and prevent antibiotic resistant infection of the eye, ear, skin and other sites caused by enterococci and staphylococci. Enterococci and staphylococci are leading causes of multidrug resistant infection, particularly in hospitalized patients. His group identifies traits on mobile elements that destabilize the host commensal relationship, determine their origin, and define how they undermine the balance. These studies employ epidemiology, molecular genetics and genomics, cell biology and pathogenesis in animal models.